Drug Trial Radar · NCT05624424
Effect of Rematazolam Besylate, Propofol, and Sevoflurane Perioperative Sedation on Incidence of Emergence Agitation and Hemodynamics in Patients Undergoing Laparoscopic Abdominal Surgery
Last checked: Nov 19, 2026Latest source record: Nov 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,317
Planned (sponsor's estimate)
Start
Nov 15, 2022
Primary completion
Oct 31, 2023
Study completion Oct 31, 2023
Sponsor
- Lead sponsor
- Second Affiliated Hospital of Nanchang UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Yichang Humanwell Pharmaceutical Co., Ltd., China
- First posted
- Nov 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Emergence agitation (EA) is a transient, self-limited, non-fluctuating state of psychomotor excitement, which closely revolves around the emergence of general anesthesia. Uncontrolled EA during the recovery period increases the potential risk of injury to patients and medical staff, resulting in varying degrees of adverse consequences, such as elevated blood pressure, incision rupture, bleeding, cardio-cerebrovascular accidents and so on, leading to a great waste of resources. Accumulating scientific evidence indicates that the incidence of EA is related to the use of perioperative sedative drugs. As a novel ultra-short-acting benzodiazepines drugs, Remimazolam has been accepted for induction and maintenance of clinical anesthesia. Compared to traditional benzodiazepines drugs, Remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. This study aims to investigate whether perioperative sedation of Remimazolam besylate, propofol, and sevoflurane have different effects on the incidence of emergence agitation and hemodynamics in patients undergoing laparoscopic abdominal surgery.
Conditions
- Emergence Agitation
- Remimazolam Besylate
- Perioperative Sedation
- Laparoscopic Abdominal Surgery
- Anesthesia, General
Interventions
Rematazolam BesylateDrug
Anesthesia was induced with Rematazolam Besylate 0.3\~0.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by remimazolam 1-3 mg/kg/h until the end of surgery.
PropofolDrug
Anesthesia was induced with Propofol 2\~2.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by remimazolam 5\~12 mg/kg/h until the end of surgery.
SevofluraneDrug
Anesthesia was induced with etomidate 0.03 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by 2 %-3 % Sevoflorane until the end of surgery.
SufentanilDrug
Anesthesia was induced with Sufentanil 0.3\~0.5 ug/kg by intravenous injection after the LoC and BIS\<60.
Cisatracurium BesylateDrug
Anesthesia was induced with cisatracurium besilate 0.2-0.3 mg/kg by intravenous injection after the LoC and BIS\<60, followed by 0.1 mg/kg/h Cisatracurium Besylate during the operation.
RemifentanilDrug
After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of emergence agitationTime frame: Duration from the time patients awakening to the time of departure from post-anesthesia care unit (PACU), average 1 hour.
- The incidence of emergence agitationTime frame: Duration from the time patients awakening to the time of departure from PACU, average 1 hour.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
People's Hospital of Ganzhou
Ganzhou, Jiangxi, China
the First Affiliated Hospital of Gannan Medical College, Gannan Medical College
Ganzhou, Jiangxi, China
The First People's Hospital of JiuJiang
Jiujiang, Jiangxi, China
the Second Affiliated Hospital of Nanchang University, Nanchang University
Nanchang, Jiangxi, China
Tumor Hospital of Jiangxi Province
Nanchang, Jiangxi, China
Shangrao People's Hospital
Shangrao, Jiangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.